Mapping the genomic and transcriptomic features associated with telomere maintenance mechanisms in complex karyotype sarcomas
Nicola Biondi, Maria Luisa Ratto, Rajesh Pal, Tobias RauschiD, Stefanie Stirl, Laura VillacortaiD, Armin Hadzic, Caroline KnotziD, Lina SieverlingiD, Miguel A. González-WogeiD, Katrin Pfütze, Christina Geörg, Cihan ErkutiD, Umut ToprakiD, Sabine A. StainczykiD, Maria‐Veronica TeleanuiD, Simon KreutzfeldtiD, Peter HorakiD, Christoph HeiningiD, Daniel HübschmanniD, Bernd KasperiD, Peter HohenbergeriD, Klaus Schulze‐OsthoffiD, Ulrich KeilholziD, Damian Rieke Lang, , Priya ChudasamaiD
Abstract
Complex karyotype sarcomas (CKS) are heterogeneous mesenchymal malignancies that typically lack recurrent actionable oncogenic drivers and remain therapeutically challenging. Loss of ATRX is a recurrent feature of CKS and defines a particularly high-risk subgroup. ATRX loss is also associated with activation of the alternative lengthening of telomeres (ALT) pathway, and ALT-positive sarcomas have been linked to poor clinical outcomes. However, the molecular underpinnings underlying ALT-status-dependent differences in CKS, as well as the therapeutic vulnerabilities associated with ALT, remain poorly defined. By integrating C-circle-based ALT detection across 776 sarcoma samples with multi-modal sequencing of five CKS subtypes, we find that ALT activity is associated with enriched hallmarks of genomic instability. ALT-positive transcriptomes are dominated by a coordinated DNA damage response and mitotic program, in contrast to oncogenic signaling pathways that drive TERT activation in ALT-negative tumors. Long-read sequencing reveals telomere repeat clusters and telomere-mediated healing at structural breakpoints in ALT-positive tumors. These events also occur on extrachromosomal DNA (ecDNA), linking ALT activity to ecDNA biology. Together, our findings position ALT status as an important stratifying feature of CKS and identify ALT-associated transcriptional programs as potential therapeutic targets.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of function of Atrx leads to activation of alternative lengthening of telomeres in a primary mouse model of sarcoma
M. Pierpoint, W. Floyd, … D. G. Kirsch·bioRxiv·Nov 6, 2023
- Alternative Lengthening of Telomeres and CINSARC are interconnected toward non-translocation-related sarcomas progression
Gaëlle Pérot, Clémence Guerriau, … Frédéric Chibon·BMC CancerPeer-reviewed·Jun 9, 2026
- SMARCAL1 is a candidate therapeutic target for ALT-positive tumors
Angelo Taglialatela, Jina Lee, … Alberto Ciccia·bioRxiv·Feb 16, 2026
- SLFN11 puts the brakes on Alternative lengthening of telomeres
Prashant Khandagale, Allison L Welter, … Yves G. Pommier·bioRxiv·Dec 11, 2025
- Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance
- Tabular foundation model predicts alternative lengthening of telomeres (ALT) and identifies SMARCAL1 as a target in ALT-driven cancers
Declan Bennett, Monika Wierdl, … Lillian M. Guenther·bioRxiv·May 28, 2026